Celsion Co. (NASDAQ:CLSN) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 2,954,953 shares, a growth of 399.7% from the February 28th total of 591,323 shares. Based on an average daily volume of 2,928,798 shares, the short-interest ratio is currently 1.0 days. Currently, 5.7% of the shares of the company are short sold.
A hedge fund recently raised its stake in Celsion stock. Seizert Capital Partners LLC boosted its stake in shares of Celsion Co. (NASDAQ:CLSN) by 35.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 162,825 shares of the biotechnology company’s stock after buying an additional 42,803 shares during the period. Seizert Capital Partners LLC owned about 0.63% of Celsion worth $199,000 at the end of the most recent quarter. 10.74% of the stock is owned by institutional investors.
Shares of Celsion (NASDAQ:CLSN) traded down 1.36% during trading on Friday, reaching $0.29. 563,969 shares of the company’s stock were exchanged. Celsion has a 52 week low of $0.19 and a 52 week high of $1.72. The company’s 50-day moving average price is $0.28 and its 200 day moving average price is $0.54. The firm’s market capitalization is $16.09 million.
Several research analysts have issued reports on the stock. Zacks Investment Research raised shares of Celsion from a “sell” rating to a “buy” rating and set a $0.50 price objective on the stock in a research report on Friday, January 20th. Maxim Group reaffirmed a “hold” rating on shares of Celsion in a report on Thursday, March 16th. HC Wainwright reaffirmed a “buy” rating and issued a $1.50 target price on shares of Celsion in a report on Monday, April 10th. Finally, Rodman & Renshaw reissued a “buy” rating and set a $1.50 price objective on shares of Celsion in a report on Monday, April 10th.
COPYRIGHT VIOLATION WARNING: This article was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://transcriptdaily.com/2017/04/22/celsion-co-clsn-sees-significant-increase-in-short-interest.html.
About Celsion
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
